In lung adenocarcinomas patients, EGFR mediates the activation of RET with neuroendocrine differentiation characterized by ASCL1 expression, implicating that EGFR is a key regulator of RET (Tang et al., 2015). The gene discussed is RET; the disease is lung adenocarcinoma.